Progenics Pharmaceuticals, Inc. And Ono Pharmaceutical Company, Ltd. Announce Agreement to Develop and Commercialize RELISTOR in Japan

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528) today announced an exclusive license agreement under which Ono has acquired the rights to RELISTOR® (methylnaltrexone bromide) in Japan, where it plans to develop and commercialize the U.S.-approved drug for the treatment of opioid-induced constipation. RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE).